ERBB2 and breast cancer: The team around Christoph A. Klein pioneered the analysis of chromosomal imbalances in single tumor cells during BC progression using comparative genomic hybridization (CGH) as well as PCR-based analysis of loss-of-heterozygosity (LOH) and of HER2 amplification [207].